Literature DB >> 27352201

Clinical Significance of FDG-PET to Predict Pathologic Tumor Invasion and Lymph Node Metastasis of Superficial Esophageal Squamous Cell Carcinoma.

Takaoki Furukawa1, Yoichi Hamai2, Jun Hihara1, Manabu Emi1, Ichiko Yamakita1, Yuta Ibuki1, Morihito Okada1.   

Abstract

PURPOSE: To determine the preoperative ability of [18F]-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) to predict pathologic tumor invasion and lymph node status in cT1N0M0 esophageal squamous cell carcinoma (ESCC).
METHODS: We retrospectively analyzed 40 consecutive patients diagnosed with cT1N0M0 ESCC between February 2006 and April 2011. All patients were treated by esophagectomy with two- or three-field lymphadenectomy without neoadjuvant therapy. We evaluated the relevance between clinical variables including maximum standardized uptake values (SUVmax) of the primary tumor on FDG-PET and pathologic tumor invasion and lymph node status using a logistic regression model.
RESULTS: Tumors invaded the middle submucosal layer (SM2) and beyond in 21 (52.5 %) patients, and 6 (15 %) had lymph node metastases. The areas under receiver operating characteristic (ROC) curves for SUVmax of the primary tumor used to predict factors involved in tumor infiltration to SM2 or deeper and lymph node metastasis were 0.75 (p = 0.006) and 0.79 (p = 0.025), respectively. The optimal SUVmax cutoff was 2.7. The findings of univariate and multivariate analyses identified SUVmax as the only significant preoperative predictor associated with tumor infiltration into SM2 or beyond and lymph node metastasis. Furthermore, SUVmax ≥ 2.7 of the primary tumor on FDG-PET was associated with poor recurrence-free and disease-specific survival (p = 0.019 and p = 0.012, respectively).
CONCLUSIONS: FDG-PET is helpful for diagnosing tumors that can infiltrate SM2 and beyond as well as occult lymph node metastasis of cT1N0M0 ESCC that are valuable indications in deciding therapeutic strategies for superficial ESCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27352201     DOI: 10.1245/s10434-016-5359-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Kingo Hirasawa; Toshihoro Misumi; Masaharu Hata; Chikara Kunisaki
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

2.  Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study.

Authors:  Yutaka Miyawaki; Hiroshi Sato; Naoto Fujiwara; Shuichiro Oya; Hirofumi Sugita; Yasumitsu Hirano; Tomohiko Yamane; Shinichi Sakuramoto; Kojun Okamoto; Shigeki Yamaguchi; Isamu Koyama
Journal:  Int J Clin Oncol       Date:  2019-12-23       Impact factor: 3.402

Review 3.  Primary cerebral malignant melanoma in insular region with extracranial metastasis: case report and review literature.

Authors:  Marta Troya-Castilla; Santiago Rocha-Romero; Yamin Chocrón-González; Francisco Javier Márquez-Rivas
Journal:  World J Surg Oncol       Date:  2016-09-01       Impact factor: 2.754

4.  Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis.

Authors:  Jingfeng Hu; Dengyan Zhu; Yang Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma.

Authors:  Kazuhiro Toriyama; Masahiro Tajika; Tsutomu Tanaka; Makoto Ishihara; Yutaka Hirayama; Sachiyo Onishi; Nobumasa Mizuno; Takamichi Kuwahara; Nozomi Okuno; Shinpei Matsumoto; Eiichi Sasaki; Tetsuya Abe; Yasushi Yatabe; Kazuo Hara; Keitaro Matsuo; Tsuneo Tamaki; Yasumasa Niwa
Journal:  World J Gastroenterol       Date:  2019-12-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.